ImmVira

📍 Hong Kong, Hong Kong SAR🗓 Founded 2015👥 14 employees💰 Last funded Dec 2020
Biotechnology🌐 immvira-theravir.com
Website LinkedIn
VISION ABOVE AND BEYOND Immvira was founded in May of 2015 by Prof. Bernard Roizman of University of Chicago and Prof. Grace Zhou formerly a Research Associate Professor at University of Chicago, Prof. Thomas Shenk of Princeton University, Prof. Richard Whitley of University of Alabama, Prof. Ralph Weichselbaum of University of Chicago. Our mission is to develop a broad range of anti-cancer therapies based on genetically engineered viruses and augmented by cancer specific immune factors or chemotherapeutic agents that can be delivered intratumorally or systemically. Our lead candidate, a oHSV encoding IL12 and anti-PD-1Ab (T3) is designed to be administered by direct injection into the tumor mass. In murine tests it is more potent and would be expected to lack the toxicity associated with the systemic administration of immunomodulators alone. Product line 1 already entered clinical trials in January of 2019.
2
Total investors
0
Early stage
2
Mid stage
0
Late stage
2015
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United States
1
China
1
Frequently asked questions
Who invested in ImmVira?
ImmVira has 2 investors on record on gritt.io, 2 mid-stage.
When did ImmVira last raise funding?
The most recent investment in ImmVira recorded on gritt.io was in December 2020.
When was ImmVira founded?
ImmVira was founded in 2015.
What industry is ImmVira in?
ImmVira operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is ImmVira based?
ImmVira is headquartered in Hong Kong, Hong Kong SAR.